Pfizer's $11.6 billion Biohaven buy could spark more biotech deals

May 11, 2022 · PFE. BHVN. By Manas Mishra. (Reuters) - Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it …

CouponFollow Extension

$11
OFF

Pfizer's $11.6 Billion Biohaven Buy Could Spark More Biotech Deals

1 week from now

May 11, 2022 · PFE. BHVN. By Manas Mishra. (Reuters) - Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it …

yahoo.com

6%
OFF

Pfizer's $11.6 Bn Biohaven Buy Could Spark More Biotech Deals

1 week from now

May 12, 2022 · Pfizer offered a 78.6% premium, or $148.50 per Biohaven share, but that was below the $151.51 price Biohaven shares traded at in October before the months-long selloff …

indiatimes.com

$11
OFF

Pfizer's $11.6 Bn Biohaven Buy Could Spark More Biotech Deals

1 week from now

May 11, 2022 · Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush …

indiatimes.com

$11
OFF

Pfizer's $11.6 Bln Biohaven Buy Could Spark More Biotech Deals

1 week from now

May 11, 2022 · Pfizer Inc’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-fl… Skip to …

financialpost.com

6%
OFF

Pfizer's $11.6 Billion Biohaven Buy Could Spark More Biotech Deals

1 week from now

Pfizer offered a 78.6% premium, or $148.50 per Biohaven share, but that was below the $151.51 price Biohaven shares traded at in October before the months-long selloff in the sector began.

investing.com

$11
OFF

Pfizer’s $11.6 Billion Biohaven Buy Could Spark More Biotech Deals

1 week from now

May 11, 2022 · By Manas Mishra (Reuters) – Pfizer Inc’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more …

financialnewsletter.com

$11
OFF

Pfizer's $11.6 Bln Biohaven Buy Could Spark More Biotech Deals

1 week from now

By Manas Mishra. May 11 (Reuters) - Pfizer Inc's PFE $11.6 billion deal for migraine specialist Biohaven Pharmaceutical BHVN has kindled expectations on Wall Street that it may usher in …

webull.com

$11
OFF

Pfizer To Buy Biohaven Pharmaceutical In $11.6 Bln Deal

1 week from now

May 10 (Reuters) - Pfizer Inc PFE.N said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd BHVN.N for about $11.6 billion in cash. Pfizer will …

nasdaq.com

$11
OFF

Pfizer To Buy Biohaven For $11.6 Billion | C&EN Global Enterprise

1 week from now

May 16, 2022 · Seeking Nurtec, a pill approved to treat and prevent migraine in adults, Pfizer has agreed to acquire its maker, Biohaven Pharmaceuticals, in a cash deal valued at $11.6 billion. …

acs.org

$11
OFF

Pfizer To Pay $11.6 Billion For Biohaven To Tap Migraine Market

1 week from now

Pfizer Inc said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine …

yahoo.com

$148.50
OFF

Pfizer Completes Acquisition Of Biohaven Pharmaceuticals

1 week from now

Oct 3, 2022 · Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately …

pfizer.com

FAQs about Pfizer's $11.6 billion Biohaven buy could spark more biotech deals Coupon?

Will Pfizer buy Biohaven?

May 10 (Reuters) - Pfizer Inc PFE.N said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd BHVN.N for about $11.6 billion in cash. Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price. ...

Will Pfizer's Biohaven deal usher in more buyouts?

(Reuters) - Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs. ...

What happened to Biohaven Pharmaceuticals?

The rest of Biohaven’s pipeline will be spun out into a new company led by the biotech’s current CEO and retaining its name. Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on its future growth. ...

Will Pfizer buy migraine drug maker Biohaven?

Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash. May 10 (Reuters) - Pfizer Inc PFE.N said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd BHVN.N for about $11.6 billion in cash. ...

How much will Biohaven shareholders receive?

Biohaven shareholders will receive 0.5 shares of the new company for each share of Biohaven stock they currently own. Along with much of the biotech sector, Biohaven's shares had fallen sharply in recent months, losing 45% of their value since they hit $151.26 in October. ...

Will Pfizer buy Medivation?

The deal is Pfizer’s largest since its 2016 purchase of Medivation for $14.3bn. Analysts have expected a dealmaking boom after a biotech sell-off earlier this year hit valuations, creating opportunities for Big Pharma. ...